All News

Conv3.jpg

ACR 2024 - Day 2 Report

d Jack Cush, MD

Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.

Read Article
bathroom scale

Shedding Weight and Pain: The Promise of Anti-Obesity Medications in RA

d Caoilfhionn Marie Connolly, MD

With the advent of FDA-approved anti-obesity medications such as semaglutide and tirzepatide, a new avenue for managing this challenging patient population has emerged. But how might these drugs impact the trajectory of RA, and are we on the cusp of a paradigm shift?

Read Article
question-mark-1872634_640.jpg

JAKi in inflammatory myositis?

d Janet Pope, MD, MPH, FRCPC

Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.

Read Article
3D management of Sscl from @delgaldoFrances -Time -Severity -Type of organ involvement *Identify phenotypes: fibrotic vs vascular damage. *Raynaud’s red flags: +ANA, puffy fingers, abn capillaroscopy. *Early ttnt of of digital ulcers delays onset of PAH. *High IFN-I =marker of… https://t.co/ByfuV0MJds https://t.co/GdRVwuRf4E

Links:

Adela Castro AdelaCastro222 ( View Tweet)
My ramblings on the SELECT-GCA study and predictions of the place of upadacitinib in clinical practice in GCA are up now on RheumNow #ACR24 @RheumNow https://t.co/DR5VgVmdse

Links:

Richard Conway RichardPAConway ( View Tweet)

I've shared some further thoughts on @jeffsparks SAIL-RA study and its finding of the strong association of RA-ILD with disease activity in early RA. And of course couldn't resist going on a tangent about the ACR ILD guidelines! #ACR24 @RheumNow https://t.co/UUDbWw38Im

Links:

Richard Conway RichardPAConway ( View Tweet)

A key practice changing study (I hope) from #ACR24 has been the preCARA study. Fertility increases with aggressive disease control. My video on this study is up now on @RheumNow https://t.co/Pf3rdTHbOJ

Links:

Richard Conway RichardPAConway ( View Tweet)

The TAPIR study presented at #ACR24 may not be as attention grabbing as others like SELECT-GCA, but in my opinion it is arguablyone of the most important ANCA-vasculitis studies ever. I've shared some further thoughs in an article on @RheumNow https://t.co/mImAE8ezSQ

Links:

Richard Conway RichardPAConway ( View Tweet)

RheumNow Day 2 Recap: ACR Convergence 2024 Highlights https://t.co/YAwOEaNsWs

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

Dr. John Cush RheumNow ( View Tweet)

We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition? Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt NO difference in relapse rate at 26, 52 wks despite addition of Anakinra @RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)

VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
To stop tsDMARD / bDMARD To improve #COVIDVACCINE response in those w several previous #COVID19 #vaccinations is NOT necessary This will change my practice! #ACR24 @RheumNow @ACRheum https://t.co/WXeqMOEfuA

Links:

Janet Pope Janetbirdope ( View Tweet)

What a result!!! Crowed split 49% against and 51% for MCTD as a unique disease entity Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group Fantastic session from all the presenters @RheumNow #ACR24 https://t.co/GgTVQ1VNWP

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)

Super helpful results from COVER study, holding JAK or IL17 for COVID boosters Antibody titers went up regardless of holding Holding caused flares (14-25% increase!) Pretty clear message; continue JAK / IL17 #ACR24 @RheumNow Abstr#1718 #ACRbest https://t.co/Mf89dWrRWz

Links:

Mike Putman EBRheum ( View Tweet)
Would be helpful for us (and pts) to better understand rimmunotherapy agent specific risk on subsequent GCA/PMR AFTRER propensity matching of >7k pt on combo nivolumab/ipilimumab compared to pembrolizumab: - PMR RR 3.8x N/I vs. P - no diff in GCA risk @RheumNow #ACR24 https://t.co/IF4Gh7Cumd

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
🔶Clinical Year in Review #ACR24 🔶 Talk By @MHPillingerMD • Review some of the most impactful studies in Rheumatology from the past year! #RheumTwitter #Rheumatology https://t.co/1ULDB2l4gX

Links:

Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
The anti-MCTD group strikes back Of cohort of over 1,000 RNP+ pt, only 17 clinically diagnosed with MCTD Majority of patients, despite potential overlap, treated for other primary rheum dz @RheumNow #ACR24 https://t.co/vkQ6UPs34y

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Older RA patients in RISE with high disease activity show a higher incidence of hip and major osteoporotic fractures. Practice T2T and monitor bone health closely! #ACR24 @RheumNow ABST#1748 https://t.co/7MCAIrfXhp

Links:

Jiha Lee JihaRheum ( View Tweet)
Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO. There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies. Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr

Links:

Adela Castro AdelaCastro222 ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×